Ji-Hye Park

Bowen's disease and bowenoid actinic keratosis share overlapping clinical and histopathological features, and there is no clear consensus regarding their differential diagnosis. This study aimed to identify clinicopathological differences between the two diseases and to develop a diagnostic prediction model in a Korean population. We retrospectively analyzed 253 patients pathologically diagnosed with Bowen's disease or bowenoid actinic keratosis at a single institution in South Korea. Clinical and histopathological variables were compared between the two groups, and significant variables were incorporated into a multivariable logistic regression model. The model was externally validated using an independent cohort of 207 patients from another institution in South Korea. In the development cohort, variables significantly associated with diagnosis included lesion location, adjacent pigmented lesions, solar elastosis, pathologically identical lesions in the same region, and the number of atypical cells within a 3 mm width of the epidermis. The prediction model showed good discriminative performance, with an area under the receiver operating characteristic curve of 0.897. In the external validation cohort, the model demonstrated excellent performance, with an area under the curve of 0.994 and an accuracy of 95.17%. These findings suggest that integration of clinical and histopathological features may help differentiate Bowen's disease from bowenoid actinic keratosis in Korean clinical settings. Further validation in ethnically and geographically diverse populations is needed before broader application of the proposed model.

Purpose: Xerosis and pruritus are common dermatological complications in patients undergoing maintenance hemodialysis. However, evidence supporting the effectiveness of moisturizers in this population remains limited. This study evaluated the effects of a topical moisturizer on uremic xerosis and skin hydration in patients undergoing hemodialysis.Methods: We enrolled 21 patients undergoing maintenance hemodialysis who had skin dryness and itching; 20 completed the 4-week intervention and were included in the analysis. The participants applied a moisturizer containing ceramide NP, a ceramide composed of non-hydroxy fatty acids (N) and phytosphingosine (P), twice daily to the abdomen and right shin for 4 weeks. Skin hydration, transepidermal water loss (TEWL), erythema index, and melanin index were measured along with clinical assessments, including modified Eczema Area and Severity Index (mEASI) and Investigator’s Global Assessment (IGA), and patient-reported satisfaction.Results: Skin hydration increased significantly at weeks 2 and 4 at both sites compared to baseline (all P< 0.0001), whereas TEWL did not change significantly at either site. The mEASI score in the abdomen decreased significantly at week 4 (P= 0.012). Although IGA improvement was more frequent at week 4, the difference was not statistically significant. Overall, 85% of the patients reported satisfaction with symptom improvement.Conclusion: Regular application of a moisturizer was associated with a preliminary improvement in stratum corneum hydration and xerosis-related symptoms in patients undergoing hemodialysis, suggesting its potential role as a practical skin care intervention.

Oh S, et al. Ann Dermatol. 2026 ;38:e79. https://doi.org/10.5021/ad.26.126

Oh S, et al. Ann Dermatol. 2026 ;38:e76. https://doi.org/10.5021/ad.26.119

Park J, et al. Ann Dermatol. 2026 ;38:e63. https://doi.org/10.5021/ad.26.069

Background: TRTP‐101 is a novel regenerative therapy consisting of autologous adipose‐derived mesenchymal stem cells (ADMSCs) formed into three‐dimensional (3D) microtissues (microblocks, MiBs). The living 3D MiBs are designed to be extracellular matrix–enriched and organoid/tissue‐like, supporting sustained trophic signaling following intradermal delivery for atrophic scars. Objectives: This study was conducted to assess the safety and tolerability of TRTP‐101 in adults with atrophic scars. Methods: In this first‐in‐human, Phase I, single‐arm pilot study, adults (≥ 19 years) with atrophic scars meeting prespecified criteria underwent autologous adipose harvest from the abdomen and subsequent intradermal administration of TRTP‐101 (1 × 10 ⁷ cells/mL; up to 0.2 mL per scar) into four target scars per participant. Safety was the primary endpoint. Exploratory efficacy was assessed using percentage change in depression volume measured by 3D image analysis at Weeks 1, 4, 8, 12, and 24, with follow‐up extending up to 1 year. Results: Three participants received TRTP‐101 and completed 1‐year follow‐up. No dose‐limiting toxicities, treatment‐related adverse events, or late‐onset reactions were observed throughout the follow‐up period. The mean percentage reductions in atrophic scar volume were 21.27%, 19.72%, 18.88%, and 26.60% at Weeks 1, 4, 8, and 12, respectively, with a mean reduction of 19.31% at 1 year. Conclusions: A single intradermal administration of TRTP‐101 was well tolerated throughout 1 year and showed early, quantifiable reductions in scar depression volume, with a mean reduction still observed at 1 year. This first‐in‐human study may provide preliminary support for the safety and potential regenerative role of autologous ADMSC‐derived 3D MiBs for atrophic scars and supports further controlled clinical evaluation. Trial Registration : ClinicalTrials.gov NCT06210919 (first posted January 18, 2024) and NCT06435884 (first posted May 30, 2024)

Purpose: This review summarizes nail changes associated with non-infectious dermatologic diseases and describes these manifestations using appropriate medical terminology. It aims to assist clinicians in recognizing nail alterations, incorporating these findings into the diagnostic evaluation of skin disorders, and improving the management of both nail and cutaneous diseases.Current Concepts: Although nails account for only about 0.1% to 0.2% of the total body surface area, they serve critical functional and protective roles. By reinforcing and safeguarding the distal digits, nails enhance grip strength and fine motor coordination. Structurally composed of hard keratin, similar to hair, the nail unit is designed to support these mechanical functions. When affected by disease, nails may become brittle or thickened and exhibit color changes, such as yellow, white, or black discoloration. These alterations may arise from primary nail disorders or develop secondarily from underlying dermatologic diseases.Discussion and Conclusion: Inflammatory skin conditions such as lichen planus, atopic dermatitis, and psoriasis, as well as connective tissue diseases including lupus erythematosus, systemic sclerosis, and dermatomyositis, may involve the nail unit and produce characteristic changes. Some alterations are disease-specific and aid in diagnosis, whereas others overlap across conditions, requiring clinical correlation with cutaneous findings and histopathologic evaluation for confirmation. Treating the underlying skin disease often leads to improvement in nail changes; however, in some cases, nail abnormalities may persist and require targeted management strategies independent of primary dermatologic therapy.

Lee WJ, et al. Ann Dermatol. 2024 Dec;37:e1. https://doi.org/10.5021/ad.24.120

Kim H, et al. Ann Dermatol. 2024 Oct;36:e65. https://doi.org/10.5021/ad.24.084

Jung YJ, et al. Ann Dermatol. 2024 Sep;36:e62. https://doi.org/10.5021/ad.24.086